matt: celgene is going to buy juno?e is going to buy newly issued shares in juneau but is not buying the entire company. they will own a stake in the company. matt: but 26% premium. julie: apollo education owner of the university of phoenix cutting its profit and sales forecast saying it now may replace some of its two your programs with a certification program. shares are down 13%. matt: matt: university of phoenix. thanks. david balin, still with us. let's get back to what we saw come out of greece. an interesting twist in the story could be what happens between now and the referendum. someone tweeted into surveillance this morning that they thought tsipras would make a deal before the referendum to save his job or at least save his party's leadership in greece. david: the question is, what is his endgame? if his endgame is to get the best deal he can for grace and have the issue of how much that they have outstanding dealt with, that would argue against that. no deal in the interim would deal with the complexities of

you are the man. >> much better than a substitute teacher. >> thank you. >> celgene!s lower in the after-market. you buy on this weakness in the juno headline. >> i'm simon hobbs. catch more "fast money" tomorrow at jim starts right now. >> my mission is simple, to make you money. i'm here to level the playing field for all investors. there is always a bull market somewhere and i promise to help you find it. mad money starts now. >>> hey i'm cramer. welcome to mad money. welcome to cramerica. my job is to explain this stuff, to teach you. call or tweet me. what the heck were those early morning tip buyers thinking. when the market looks

celgene has stakes in companies.his is one as they've anointed june know and i think a lot of people feel it was an overpay but you need a chip in personalized cancer. that is the future. gene sequencing. >> up $14 right now. we'll keep a close eye on those. coming up we have jim's mad dash. let's look at the futures. we are looking for an up open this morning. more "squawk on the street" coming right at you. here at the td ameritrade trader group, they work all the time. sup jj? working hard? working 24/7 on mobile trader, rated #1 trading app in the app store. it lets you trade stocks options, futures... even advanced orders. and it offers more charts than a lot of the other competitors do in desktop. you work so late. i guess you don't see your family very much? i see them all the time. did you finish your derivative pricing model, honey? for all the confidence you need. td ameritrade. you got this. verizon say neversettle. t-mobile agrees. never settle for verizon's overpriced gimmicks. try the un-carrier risk-fr

celgene down slightly on the news.ey are going to level t-cell therapeutic strategies for patients with cancer announcing a ten-year collaboration between celgene and juno. >> we are talking about a $4 billion market cap company. this is huge. thank you. >>> up next dupont's ceo ellen kullman. >> some investors see apple as a safe haven play but that stock down nearly 2% today. >>> dupont is taking a hit in the market sell-off today. one of the biggest losers on the dow amid analyst downgrade when investors are watching what's happening overseas. dupont has operations in 90 countries including greece and china. joining me isselen kullman, ceo of dupont. welcome. you just rang the closing bell. >> we did very exciting. >> you guys have a couple of spin-offs. first though give as sense how worried you are in the boardroom or in the c-suite about the turmoil in greece and growth concerns in china. >> it's interesting because 213-year-old we've seen a lot. nevertheless the economy, the world keeps throwing things at us. gr

celgene the same story and snap-on tools, twelve 12 stocks up nine out of the last ten years and onen the entire s&p 500, that's been up 100% of the time over the last ten years in the month of july and that's big blue ibm, up an average of 6%. it's been up ten out of the last ten julys so there you have it, tyler. one stock to watch. not saying this is all going to happen the way it has happened in the past. not an indicator of future performance. still historically context-wise for the last decade interesting that these stocks tend to outperform tyler, in the month of july. back over to you. >> and for more on dom's story about market performance in july please visit powerlunch.cnbc.com. all right. drama in greece. still no resolution as we push towards a possible sunday really a probable stunned referendum over in that country. the greek etf having an awful week, one week down about 19%, and then there's the yield on the ten-year greek bond. the yield is 15.4%. compare that about 2.2% for the u.s. bond. michelle caruso-cabrera is live where there is a demonstration going on in ath

celgene will pay the company and get the right to commercialize the therapies. you, julie.: greece dominated headlines today during the stock selloff. what else did you miss? we begin with puerto rico's debt debacle. laura keller joins us now. at 9:30 last night, i got an alert that says the governor or puerto rico since the debt is not sustainable. how much of a surprise is this? laura: what we have known about puerto rico, it is not a surprise. the way it was announced in a media article was certainly not the normal way this happens. normally, this happens in private conversations. this is a little different. joe: puerto rico has seen its debt climb massively over the years. you can see on the chart it has climbed every year. what is the state of affairs that has caused puerto rico to pile on so much debt? laura: every year, they have overextended in terms of budget. they projected how much revenue they will raise, but collected much less. every year, they needed to paper over the shortfalls. alix: puerto rico needs to be able to declare bankruptcy and can't. laura: some

celgene wins in this. >> drop for abercrombie & fitch. zbln a great day in retail but this specifically. fbr downgraded it to market perform. and it's okay here. >> pop for pentair. 7%. pete. >> looking for this value. they position starting on may 7th and got into a full position 7% already. they're expecting the stock to go a lot higher from here. very impressive the way they did it. they did it with stocks, also did it with options. 15% of their position through options they were able to get themselves into a very large position. i think this stock's going a lot higher. >> drop for sony down 6%. bk. >> capital raise stock and bonds. tough environment to do that. if you want to play japan just short the yen. ycs is your trade. >> final day of trading for the first half of the year. one widely held dow stock is in the gutter. we'll tell you which one and if it's worth buying right now. sysco, s-y-s-c-o sysco calling off its deal with u.s. foods and getting hit in the downgrade. we've got all the details ahead on "fast money." >>> we've g

is that what celgene needs from you? >> i think they are a great science company.s successful as they are developing drugs and actually buying assets you have to understand the basic science. now, i do think we enrich their scientific credentials. our company is focused on t-cell biology and how you use them to fight cancer. that's something we think our company is very good at. >> i think it's okay for you to say, yeah they needed some additional research bona fides in t-cells. you don't have to say they knew everything. right? they came to you for a reason didn't they? >> good partnerships are based on making both partners strong. >> well they have a $90 million market cap. >> yeah. >> what's yours? >> in the $5 billion range. >> so this is a potent alliance. >> it could be. >> in terms of t-cells, you're ramping up for certain types of cancer before the t-cells didn't recognize it as cancer? >> exactly right. cancer hides from our immune system in a number of different ways. what we do is take immune cells in the -- t-cells in particular. >> you take them out? >

now celgene is investing about 1 billion in juno therapeutics. they'll pay up front and buy a 10% stake for $93 a share. that's nearly double the closing price on monday. the ceo will be on squawk box today to discuss the deal. that's 7:15 a.m. eastern time. >> apple is officially launching it's new streaming music service today. the company is hoping that some of the more than 600 million people with itunes accounts will sign up. the questions remain over how many will stick around to pass the free trial. it costs $9.99 a month and has a live radio station with channels programmed by celebrity d.j.'s such as elton john pharell williams and drake. >> i love a bit of elton john. microsoft is handing over control of its display ad business to aol and selling mapping technology to uber. it's slimming down it's operations. microsoft will focus more on the growing search ad business and displaying maps on windows devices instead of generating maps themselves. they won't say how many jobs will be cut but reports say it's about 1200. let's have a look a

now i picked up in celgene flopping around like a fish out of water what do you see. >> the hedge fund. they need a reup of their buy back today. another $4 billion authorization. it's okay by me. by the way notice finally brouwer broke out of 109 range for solvati and they're paying for it. let's go to paul in massachusetts. >> caller: hey jim what do you think of anth pharmaceuticals. >> they have some great drug -- well it's great -- it's a development stage biotech that has great drugs for unmet needs and i say you should own it. tom in maryland. >> caller: congratulations on your last ten years. my stock is symbol tube. >> people are going to say jim this is not what tube mogul said, i don't care. this particularly kind of advertising platform i'm going with sales force.com because they coordinate a lot of these things. they were very strong yesterday. george in new jersey. >> caller: yo jim this is george from glass borough new jersey. your take on exxon. >> exxon stock is below where oil was when it was lower. this is crazy. the stocks are not reflecting the fundamentals. they'r

next thing you know celgene is rallying. so many drug approvals in the sector. think of the next generation of cholesterol drugs. market is huge. consider the tremendous data on alzheimer's. gilead keeps hitting new highs. let's not forget how good the junior bio techs can be like receptos. ground breaking drug that can treat frefrg multiple sclerosis bowel conditions are and crohn's disease. or bio jumping another for radius health which is catapulting another 5% and they are going to be on the show. these drugs are working. that is why the stocks are moving. because these are successes. and there are far fewer failures in bio tech. the strilss can lev state here. these companies have been totally hostage to a potential european slow down as well as the weak euro. with greece settled we can -- let's say we hope for better than expected guidance even if the actual quarters won't be that good. that's already baked in. look, same goes for the consumer package good stories and power plays hobbled by the strong dollar and the weakness in europe. i can't tell you how

. >> celgene! it's lower in the after-market. you buy on this weakness in the juno headline. >> i'm simon hobbs. catch more "fast money" tomorrow at jim starts right now. >> my mission is simple to make you money. i'm here to level the playing field for all investors. there is always a bull market somewhere and i promise to help you find it. mad money starts now. >>> hey i'm cramer. welcome to mad money. welcome to cramerica. my job is to explain this stuff, to teach you. call or tweet me. what the heck were those early morning tip buyers thinking. when the market looks so good. it was so rotten underneath. dow finishing down 350. s&p and nasdaq plummeting. needless to say it was the worst day of the year. i believe dips are often buying opportunities. but do you mind if we at least get one first? there there is a lot of insanity in this. do you know how many times i said i didn't like the set up. i particularly didn't like the extreme level of complacency here. ease and desire to be the firsthand over fist buyers. it was exact t

or yesterday's billion-dollar investment by celgen into juno therapeutics. are on the move to bring out things to be negative to stay negative is to miss these kinds of opportunities, i will not let you do that i wouldn't emphasize the stories if they were one-off. instead the bottom line is they make up the preponderance of the news flow away from greece and make the market too compelling to sneer at. despite the drama that controls the overall prices of the averages. even as it can't keep down the individual participants in an index, when the ceos take action necessary action to make you the shareholder, richer than you were just the day before. hey why don't we go to bob in florida. bob? >> hello, jim. >> bob. >> are you on? >> i'm more on than ever how about you? >> all right. i enjoy your show and i hope you can provide some insight into alcatel lucent. i'm a 74-year-old retiree about a year ago i started investing in alu based primarily on chairman michael kooms new shift plan aimed at increasing the bottom line. just when it looks like things are goin

celgene is the lone company that does not fit that pattern.d to think it's a board of directors making that decision. if the board makes the decision to split the stock what does the board know about what's coming to the company that leads them to believe that that is the right move to take? conventional wisdom would tell if you the board of directors does this, they would view the stock as potentially going up. if it were not to split in the other case, too. >> yeah. what is the, just, we're going to talk a lot about cannes lyon and what you two are seeing out there. is netflix talked about in circles broadly? is it the top point of discussion? does it revolve around something else? >> when it comes to a content standpoint, the big conversation amongst publishers is pressure from facebook and google and it's about selling content. when i talk to all of my colleagues here, whether, it's how to develop an additional revenue stream beyond advertising. so many of us are talking about going into television. licensing our video to other wireless pl

this is the opposite of the celgenes and gileads. this is not a one trick pony but pretty close.hat happens. big short interest about 10%. to me it's imperative that effectively holds right here 25 bucks. it's going to be a hyung volume day tomorrow. you're not buying this on valuation. but if you do see a flush tomorrow on a day it trades north of 10 million shares and it holds 25 this might be worth a look. >> let's bring in cnbc's meg tirrell for more on avalanche. dom was saying there's a conference call going on right now. have you been listening in? have you heard anything of note? >> yes, mandy, what i'm hearing right now, avalanche, what it's designed to do it's a gene therapy. what they're trying to provide here for macular degeneration which now is treated with maybe monthly or biweekly injections into the eye, now, they're trying to make that less frequent. and actually potentially only treat once with their gene therapy treatment. and then actually solve the problem. what we're seeing and hearing is people have to get follow-up ones. the company has not been pushing i

they're far more solid they trade literally like pharma names these days, the amgens of the world, celgeneyback they announced. those names still -- >> with those little guys it's a lot of trading. >> a lot of fun. >> let's get to another big after hours mover but this one's in the opposite direction and it's oracle. the earnings call is still under way. in fact, it's now well under way. cnbc's josh lipton has been monitoring that call. what more have we heard, josh? >> well, mandy, on that oracle conference call executives trying to sound a note of confidence. here's what mark herd, oracle's co-ceo, had to say. take a listen. >> we're now growing faster than both salesforce and workday. and we expect revenue growth next year could be as high in fast pass as 60%. we're doing what you very rarely ever see happen in our industry. we are getting bigger. and our growth rate is expanding. we will be the world's largest enterprise cloud company. >> ellison saying oracle's cloud business will grow faster than workday. things are good for oracle in the cloud, he said. mandy, back to you. >> okay,